CD62L downregulation may impair effector CTL immune responses in CML patients at diagnosis and abrogate anti-leukemic immune control, as CD62L is critical in controlling the traffic of T cells to secondary lymphoid tissues and priming by antigen-presenting cells. This evidence concerns the gene SELL and chronic myelogenous leukemia, BCR-ABL1 positive.